Results 151 to 160 of about 18,827 (200)

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study. [PDF]

ESMO Open
Schmidt M, Thill M, Rey J, Rautenberg B, Bjelic-Radisic V, Decker T, Rom J, Kögel M, Lübbe K, Nacke A, Seiler S, Just M, Müller V, Buss-Steidle R, Terhaag J, Mundhenke C, Denkert C, Holtschmidt J, Loibl S.   +18 more
europepmc   +1 more source

Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer. [PDF]

Breast Cancer Res
Telang S, Clem BF, Miret AAH, Price L, Dougherty SM, Schmitz A, Yin X, Ma X, Zhang X, Chesney J, Imbert-Fernandez Y.   +10 more
europepmc   +1 more source

Metastasis of triple negative breast cancer is regulated by a targetable miR-342-E2F network. [PDF]

EMBO Mol Med
Arnet VK, Johnstone CN, Redvers RP, Chambers CA, Pillman KA, Toubia J, Lumb R, Dredge BK, Bert AG, Hackett-Jones E, Pinweha P, Bracken JM, Deshpande S, Price ZK, Ortiz M, Scheer KG, Rajpal J, Geiger AB, Roslan S, Li X, O'Toole S, Beilharz TH, Bracken CP, Khew-Goodall Y, Goodall GJ, Anderson RL, Gregory PA.   +26 more
europepmc   +1 more source

CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. [PDF]

Cell Death Dis
Moresi F, Japón-Ruiz D, Serra M, Ávalos-Moreno M, Garcia E, Coulonval K, Pavesi A, Beck B, Bisteau X.   +8 more
europepmc   +1 more source

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection. [PDF]

Cancer
Williams AD, Weiss A.
europepmc   +1 more source

Correction to 'The kinase inhibitor palbociclib binds to HIV TAR RNA with very low nanomolar affinity and exquisite specificity'. [PDF]

Nucleic Acids Res
europepmc   +1 more source

Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary. [PDF]

Future Oncol
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A.   +9 more
europepmc   +1 more source

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China. [PDF]

BMC Cancer
Guo X, Li P, Hu S, Ding Y, Xie B, Cai Y, Chen H, Li X, Guo S, Wang Y, Zhou Y, Chen Y.   +11 more
europepmc   +1 more source

Efficacy and tolerability of CDK 4/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged ≥ 70 years. [PDF]

BMC Cancer
Atci MM, Erciyestepe M, Erturk K.
europepmc   +1 more source